2 news items
Larimar Therapeutics Selected By FDA To Participate In Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program For Nomlabofusp In Friedreich's Ataxia
LRMR
30 May 24
for rare diseases Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
LRMR
30 May 24
Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated
- Prev
- 1
- Next